A key result of the scRNA-seq/TCR-seq analyses in this cohort was that we defined a highly resistant subgroup of EGFR-mutant NSCLC in response to neoadjuvant immunochemotherapy, which was characterized as high infiltration and expansion of CCR8+ Treg cells and low expansion of CXCL13+ Tex cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.